MeSH term
Frequency | Condition_Probility | Adult | 56 | 0.0 |
Aged | 15 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Erythrocytes/*enzymology | 20 | 3.0 |
Female | 47 | 0.0 |
Heme/metabolism | 2 | 7.0 |
Humans | 126 | 0.0 |
Male | 88 | 0.0 |
Middle Aged | 42 | 0.0 |
Porphobilinogen Synthase/*blood | 19 | 95.0 |
Research Support, Non-U.S. Gov't | 57 | 0.0 |
Child | 13 | 0.0 |
Child, Preschool | 7 | 0.0 |
*Environmental Exposure | 5 | 6.0 |
Genotype | 16 | 0.0 |
Lead/*blood | 16 | 69.0 |
Lead Poisoning/*etiology | 2 | 100.0 |
Porphobilinogen Synthase/*genetics | 22 | 91.0 |
Biological Markers/analysis | 2 | 0.0 |
Heme/biosynthesis | 3 | 16.0 |
Industry | 2 | 6.0 |
Korea | 7 | 3.0 |
*Occupational Exposure | 10 | 7.0 |
Porphobilinogen Synthase/metabolism | 4 | 100.0 |
Adolescent | 19 | 0.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
English Abstract | 14 | 0.0 |
*Polymorphism, Genetic | 11 | 0.0 |
Biological Markers | 3 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Comparative Study | 24 | 0.0 |
Cross-Sectional Studies | 6 | 0.0 |
Lead/adverse effects/*metabolism | 2 | 100.0 |
Linear Models | 3 | 0.0 |
Occupational Exposure/*analysis | 7 | 26.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 35 | 0.0 |
Tibia/chemistry | 2 | 50.0 |
Tissue Distribution | 4 | 0.0 |
*Metallurgy | 2 | 22.0 |
Porphobilinogen Synthase/*metabolism | 9 | 90.0 |
Age Factors | 5 | 0.0 |
Alcohol Drinking | 2 | 1.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Environmental Exposure | 17 | 11.0 |
Lead/*adverse effects | 2 | 33.0 |
Smoking | 3 | 0.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Lysine/chemistry | 2 | 2.0 |
Models, Molecular | 3 | 0.0 |
Protein Conformation | 3 | 0.0 |
Lead/*adverse effects/blood | 5 | 62.0 |
China | 2 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Gene Frequency | 4 | 0.0 |
Polymorphism, Genetic | 9 | 0.0 |
Porphobilinogen Synthase/*genetics/metabolism | 4 | 80.0 |
Protoporphyrins/*blood | 3 | 25.0 |
Animals | 21 | 0.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Mice | 6 | 0.0 |
*Mutation | 2 | 0.0 |
Phenotype | 10 | 0.0 |
Receptors, Calcitriol/*genetics/physiology | 2 | 14.0 |
Aminolevulinic Acid/urine | 7 | 35.0 |
Erythrocytes/enzymology | 9 | 2.0 |
Germany | 2 | 0.0 |
Mutation | 5 | 0.0 |
Pedigree | 3 | 0.0 |
Porphobilinogen Synthase/blood/*deficiency/genetics | 2 | 100.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Erythrocytes/drug effects/*enzymology | 2 | 10.0 |
In Vitro | 7 | 0.0 |
Lead/pharmacology | 2 | 100.0 |
Rats | 9 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
Infusions, Parenteral | 2 | 1.0 |
Alleles | 9 | 0.0 |
Lead/blood/*toxicity | 3 | 100.0 |
Polymerase Chain Reaction | 10 | 0.0 |
Porphobilinogen Synthase/blood/*genetics | 6 | 100.0 |
Risk Factors | 5 | 0.0 |
Aminolevulinic Acid/*blood/urine | 2 | 100.0 |
Erythrocytes/metabolism | 4 | 2.0 |
Hemoglobins/*metabolism | 2 | 4.0 |
Protoporphyrins/blood | 7 | 33.0 |
Blotting, Western | 4 | 0.0 |
CHO Cells | 2 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Hamsters | 2 | 0.0 |
Porphobilinogen Synthase/deficiency/*genetics | 3 | 100.0 |
Lead Poisoning/enzymology/*genetics | 2 | 100.0 |
Base Sequence | 11 | 0.0 |
Lead/adverse effects/*blood | 2 | 100.0 |
Lead Poisoning/*genetics | 4 | 66.0 |
Molecular Sequence Data | 16 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Porphyrins/metabolism | 2 | 25.0 |
Chromosome Mapping | 3 | 0.0 |
Administration, Oral | 3 | 0.0 |
Porphobilinogen Synthase/*deficiency | 2 | 100.0 |
Time Factors | 10 | 0.0 |
Drug Interactions | 2 | 0.0 |
Occupational Exposure/*adverse effects | 3 | 3.0 |
Protein Binding | 2 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Zinc/*metabolism | 3 | 4.0 |
Amino Acid Sequence | 8 | 0.0 |
Porphobilinogen Synthase/chemistry/*genetics | 2 | 100.0 |
Porphobilinogen Synthase/*deficiency/genetics | 2 | 100.0 |
Coproporphyrins/urine | 3 | 75.0 |
Heme/*biosynthesis | 4 | 44.0 |
Porphobilinogen Synthase/*blood/genetics | 2 | 100.0 |
Saccharomyces cerevisiae/enzymology/genetics | 3 | 6.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Molecular Weight | 3 | 0.0 |
Occupational Exposure | 3 | 3.0 |
Spectrophotometry, Atomic | 3 | 6.0 |
Lead Poisoning/*blood | 3 | 42.0 |
Porphobilinogen Synthase/blood | 14 | 87.0 |
Kinetics | 7 | 0.0 |
Aminolevulinic Acid/*blood | 3 | 100.0 |
Body Burden | 3 | 16.0 |
Disease Susceptibility | 2 | 0.0 |
Environmental Monitoring | 4 | 10.0 |
Lead Poisoning/*diagnosis | 2 | 100.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Random Allocation | 2 | 0.0 |
Succimer/*administration & dosage | 2 | 100.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Plasmids | 2 | 0.0 |
Chromosomes, Human, Pair 9 | 3 | 1.0 |
Exons | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Erythrocytes/*drug effects/enzymology | 2 | 18.0 |
Maximum Allowable Concentration | 4 | 25.0 |
Metallurgy | 2 | 15.0 |
Analysis of Variance | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
5'-Nucleotidase/*blood | 2 | 100.0 |
Air Pollutants, Occupational | 2 | 100.0 |
Hematocrit | 4 | 1.0 |
*Lead/blood | 2 | 100.0 |
Lead Poisoning | 2 | 100.0 |
*Chromosomes, Human, Pair 9 | 2 | 0.0 |
Lead/*metabolism | 3 | 75.0 |
Isoenzymes/blood/genetics | 2 | 11.0 |
*Alleles | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Escherichia coli/enzymology/genetics | 2 | 3.0 |
Restriction Mapping | 3 | 0.0 |
Lead/blood | 4 | 30.0 |
Gene Frequency/genetics | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Heptanoates/pharmacology | 2 | 33.0 |
Lead/*toxicity | 3 | 33.0 |
Porphobilinogen Synthase/*antagonists & inhibitors/blood | 4 | 100.0 |
Hemoglobins/analysis | 3 | 1.0 |
Occupational Diseases/enzymology | 2 | 100.0 |
5'-Nucleotidase | 3 | 13.0 |
Ethanol/administration & dosage/*blood | 2 | 100.0 |
Lead Poisoning/*enzymology | 2 | 100.0 |
Rabbits | 2 | 0.0 |
Zinc/*pharmacology | 3 | 9.0 |
Calcium/*pharmacology | 2 | 2.0 |
Copper/*metabolism | 2 | 2.0 |
Edetic Acid/*pharmacology | 2 | 20.0 |
Occupational Diseases/*blood | 2 | 66.0 |
Japan | 2 | 0.0 |
*Occupational Medicine | 2 | 33.0 |
Sex Factors | 3 | 0.0 |
Copper/blood | 2 | 8.0 |
Lead/blood/urine | 2 | 100.0 |
Rural Population | 3 | 3.0 |
Urban Population | 3 | 2.0 |
Hydro-Lyases/*antagonists & inhibitors | 2 | 100.0 |
Lead/blood/*pharmacology | 2 | 66.0 |
Lead Poisoning/enzymology | 2 | 50.0 |
Hydro-Lyases/*blood | 8 | 100.0 |
*Aging | 2 | 1.0 |
Hydro-Lyases/*metabolism | 2 | 33.0 |
Porphobilinogen Synthase/blood/*metabolism | 2 | 100.0 |
Occupational Medicine | 3 | 60.0 |
